Business Wire

Biocodex Group Strengthens Its Position in the US Market With the Acquisition of Hilma, a Fast-Growing Natural Remedies Start-Up

Share

Biocodex, an expert in microbiota and women's health, announces that it has acquired a majority stake in Hilma, a start-up specializing in natural remedies in the United States. This acquisition is a key part of the Group’s international growth strategy and will enable Biocodex to consolidate its presence in the digestive health and women's health segments of the US market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117005739/en/

Hilma, founded by entrepreneurs Hilary Quartner, Nina Mullen, and Lily Galef, launched in January 2020 with the ambition to reimagine the medicine cabinet with effective, natural alternatives to OTC products. Hilma makes natural remedies for digestive issues, sleep, immune support, and more. Since launch, the digitally native brand has built a strong community around its best-selling digestive portfolio. They have expanded their product line to encompass everything from bloating to occasional constipation and have become a fixture in the digestive aisle at Target, among other retailers.

The Biocodex Group has been present in the US for over 20 years and is a leader in the pharmacy market with its Florastor® brand in the probiotics category. Through this acquisition, the Group aims to strengthen its position in this segment and launch its women's health activity in order to double its turnover by 2027.

Julien Dureisseix, GM of the US subsidiary, is delighted with this acquisition: "Behind Hilma, there is a simple observation: a new generation of consumers has high expectations for natural and effective products." Nicolas Coudurier, CEO of Biocodex, adds: "Hilma and Biocodex share the same goal: to be as close as possible to consumers expectations and to respond to the growing need for reliable, effective and scientifically proven natural solutions in the medicine cabinet. I am very pleased to welcome a talented team whose entrepreneurial vision and digital expertise will be invaluable in strengthening our presence in the North American market."

Nina Mullen, Co-CEO of Hilma says, “Our partnership with The Biocodex Group will enable Hilma to rapidly scale our omnichannel retail strategy, reach new audiences, and develop new products.” Hilary Quartner, Co-CEO adds, “We are thrilled to join the Biocodex family, as they share our core values of commitment to scientifically backed, natural healthcare, and building a sustainable future.” “We look forward to learning from each other and exponentially growing Hilma and The Biocodex Group brands in the US.”, notes Lily Galef, Chief Brand Officer.

ADDITIONAL INFORMATION
About Biocodex

Biocodex is a French pharmaceutical company founded in 1953 to develop and market the world’s first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®. Today, Biocodex focuses its business on three main areas: Microbiota care; Orphan diseases; Women’s health. With 1,600 employees, Biocodex generated net revenues of €418 million in 2021, including 42% in France and 58% internationally. The group is present in 124 countries through wholly owned subsidiaries in 16 countries and a network of distributors worldwide.

About Hilma

Hilma makes natural remedies that actually work for health issues like digestion, head tension, immune support and more. Hilma’s remedies are made with powerful herbs and minerals, formulated with a team of doctors, and backed by clinical research. Unlike most over-the-counter options, Hilma is made without drugs, dyes, fillers, preservatives, or artificial sweeteners. The company makes natural remedies accessible to a mainstream customer, who has embraced natural products in food, beauty, and household items, and is looking for an effective natural option for their medicine cabinet. Hilma is entirely female-founded and led. Hilma is an omnichannel brand, sold DTC on hilma.co as well as in 750+ stores, including Target, Grove Collaborative, Thrive Market, Juice Press, and Amazon.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact:
Françoise Vapillon-Burlet
f.vapillon-burlet@biocodex.com
T: +33 1 41 24 30 84

Hilma contact:
Lily Galef
lily@hilma.co

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

IonQ Unanimously Appoints Peter Chapman as Next Chairman of the Board of Directors26.4.2024 13:30:00 CEST | Press release

IonQ (NYSE: IONQ), a leader in the quantum computing industry, announced today the appointment of Peter Chapman as its next Chairman of the Board and Harry You as the Lead Independent Director of the Board, effective at the close of IonQ’s upcoming Annual General Meeting on June 5, 2024. Both appointments were disclosed in a proxy statement issued on April 25, 2024. Peter Chapman has also been nominated for re-election as a Class III director at the meeting, and his chairmanship will take effect assuming he is re-elected. “Last quarter we were delighted to have appointed Robert Cardillo and Bill Scannell to our Board of Directors. In addition, the Board unanimously appointed Peter Chapman to serve as its next Chairman following the annual meeting given his half-decade worth of contributions to IonQ and his strong progress transitioning IonQ from an academic to a commercial company,” said Niccolo de Masi, Chairman of the Nominating & Corporate Governance Committee of IonQ’s Board. “Unde

Sealing System launches: XIO – Intelligent Farming26.4.2024 12:17:00 CEST | Press release

XIO – Intelligent Farming, specializes in logistics systems for insect protein production. XIO is a new business unit within Sealing System A/S, one of the leading providers of automated end-of-line packaging lines in Scandinavia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240426832303/en/ Robotic solution handling Black Soldier Fly Larvae (Photo: Business Wire) “At Sealing System A/S, we believe that practical innovation is the engine of real-world change. With the establishment of, XIO - Intelligent Farming, we are setting new industry standards, emphasizing the importance of intralogistics in the field of insect protein production, and proudly leading the way.” Ole Jensen CEO, Sealing System A/S XIO – Intelligent Farming provides solutions serving various aspects of the insect production, including fully automatic logistics systems, comprehensive data tracking, transfer trolleys and shuttles, as well as robot systems

Tecnotree Achieves Strong Q1 2024 Results with Sustained Revenue Growth and Enhanced Profitability26.4.2024 10:46:00 CEST | Press release

Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced its financial results for the first quarter of 2024, demonstrating solid growth with a 4.7% increase in revenue. The company maintained its momentum in driving global sales of its digital platform, in the first quarter of 2024, completing many AIML and digital transformations to key customers, resulting in a significant increase in revenue. The growth was primarily driven by new wins in the LATAM region, while EMEA and APAC regions remain growing markets for the digital platform. Key Q1 Highlights of the financial results: Net sales increased 4.7% to EUR 16.3 (15.5) million. Operating results increased by 22.3% to EUR 4.4 (3.6) million. Earnings per share EUR 0.01 (0.01). Order book at the end of the period increased by 10.3% to EUR 74.8 (67.8) million. Tecnotree achieved several notable milestones in the first quarter. The company solidified its position as a trusted par

HiddenA line styled icon from Orion Icon Library.Eye